Source: Postponing OPEC, non-OPEC meeting still option for RussiaBusiness & Economy December 09, 0:35
Sports arbitration court strips Russian boxer of 2016 Olympic silverSport December 08, 22:48
Russia, US military experts, diplomats to discuss Aleppo in Geneva on Dec. 10 - LavrovWorld December 08, 22:41
Lavrov says US voiced regret over shelling of hospital in Aleppo but somewhat hazilyRussian Politics & Diplomacy December 08, 21:48
Budget revenues from Rosneft privatization to be $11.1 bln — ministerBusiness & Economy December 08, 21:18
Lavrov, Kerry discuss militants’ withdrawal from Aleppo — Russian foreign ministryRussian Politics & Diplomacy December 08, 21:00
Lavrov: Combat actions in Aleppo suspended to take civilians out of cityRussian Politics & Diplomacy December 08, 20:56
Bach says WADA to play part in deciding on 2021 IBU World Championship in RussiaSport December 08, 20:44
Gazprom signs contract for construction of Turkish Stream’s first line with AllseasBusiness & Economy December 08, 20:03
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.